Clinical Trials Directory

Trials / Completed

CompletedNCT05415904

Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools

Status
Completed
Phase
Study type
Observational
Enrollment
101 (actual)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
18 Years – 125 Years
Healthy volunteers
Not accepted

Summary

Hantaviruses are emerging pathogens responsible for hemorrhagic fever with renal syndrome. Severity risks factors aren't consensual in litterature, mostly related to scandinavian cohorts. A prognostic score was created to help patient's orientation in healthcare system but wasn't independantly validated (Hentzien, Emerging infectious diseases 2018). This retrospective cohort of hantavirus infected hospitalized adults patients in the north-eastern quarter of France between 2013 and 2022 will specify the kidney damage during infection and risk factors for a severe form (defined par acute kidney injury KDIGO 3). The previous prognostic score performance will be evaluated in this cohort.

Conditions

Interventions

TypeNameDescription
OTHERHANTA-NEObservational cohort study

Timeline

Start date
2022-05-20
Primary completion
2023-10-30
Completion
2024-07-31
First posted
2022-06-13
Last updated
2025-02-24

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05415904. Inclusion in this directory is not an endorsement.

Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools (NCT05415904) · Clinical Trials Directory